Additionally, the convenience of weekly injections with semaglutide GLP-1 versus daily injections with liraglutide is a factor many patients prefer
Current NHS eligibility criteria for semaglutide 2.4 mg (Wegovy) for weight management, according to NICE TA875, include: Body Mass Index (BMI) 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea) For people from certain high-risk ethnic groups (such as South Asian, Chinese, Black African, or African-Caribbean), lower BMI thresholds apply (typically reduced by 2.5 kg/m) Treatment must be prescribed within specialist weight management services only Treatment is limited to a maximum duration of 2 years Must be used as an adjunct to a reduced-calorie diet and increased physical activity Liraglutide 3 mg (Saxenda) availability varies significantly across NHS regions and is not routinely commissioned in many areas
Previous studies from the Prakriya laboratory showed that these channels allow calcium to flow into T-cells, helping activate the bodys immune response
This can support faster absorption and results
WHEN EACH MEDICATION MAKES SENSE Saxenda vs Zepbound: Which Should You Choose
